These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 33769468)
1. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. Gigante A; Hoffmann-Vold AM; Alunni Fegatelli D; Gabrielli A; Leodori G; Coleiro B; De Santis M; Dagna L; Alegre-Sancho JJ; Montecucco C; Carreira PE; Balbir-Gurman A; Doria A; Riemekasten G; Airò P; Distler J; Distler O; Rosato E; Rheumatology (Oxford); 2021 Dec; 61(1):213-222. PubMed ID: 33769468 [TBL] [Abstract][Full Text] [Related]
2. Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio and Cardiorenal Syndrome Type 2 in the Systemic Sclerosis EUSTAR Cohort. Colalillo A; Pellicano C; Ananyeva LP; Hachulla E; Cuomo G; Györfi AH; Czirják L; de Vries-Bouwstra J; Mouthon L; Poormoghim H; Del Galdo F; Hunzelmann N; Spierings J; Kuwana M; Rosato E; Arthritis Care Res (Hoboken); 2023 Jul; ():. PubMed ID: 37458105 [TBL] [Abstract][Full Text] [Related]
3. Estimated glomerular filtration rate and renal resistive index as possible predictive markers of mortality in systemic sclerosis. Leodori G; Pellicano C; Gigante A; Rosato E Eur J Intern Med; 2021 May; 87():83-89. PubMed ID: 33593660 [TBL] [Abstract][Full Text] [Related]
4. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Hachulla E; Clerson P; Airò P; Cuomo G; Allanore Y; Caramaschi P; Rosato E; Carreira PE; Riccieri V; Sarraco M; Denton CP; Riemekasten G; Pozzi MR; Zeni S; Mihai CM; Ullman S; Distler O; Rednic S; Smith V; Walker UA; Matucci-Cerinic M; Müller-Ladner U; Launay D; Rheumatology (Oxford); 2015 Jul; 54(7):1262-9. PubMed ID: 25596413 [TBL] [Abstract][Full Text] [Related]
5. The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort. Colalillo A; Hoffmann-Vold AM; Pellicano C; Romaniello A; Gabrielli A; Hachulla E; Smith V; Simeón-Aznar CP; Castellví I; Airò P; Truchetet ME; Siegert E; Distler O; Rosato E; Autoimmun Rev; 2023 Apr; 22(4):103290. PubMed ID: 36746368 [TBL] [Abstract][Full Text] [Related]
6. Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. Hu S; Hou Y; Wang Q; Li M; Xu D; Zeng X Arthritis Res Ther; 2018 Oct; 20(1):235. PubMed ID: 30348207 [TBL] [Abstract][Full Text] [Related]
9. Do We Have Good Activity Indices in Systemic Sclerosis? Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805 [TBL] [Abstract][Full Text] [Related]
10. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Tyndall AJ; Bannert B; Vonk M; Airò P; Cozzi F; Carreira PE; Bancel DF; Allanore Y; Müller-Ladner U; Distler O; Iannone F; Pellerito R; Pileckyte M; Miniati I; Ananieva L; Gurman AB; Damjanov N; Mueller A; Valentini G; Riemekasten G; Tikly M; Hummers L; Henriques MJ; Caramaschi P; Scheja A; Rozman B; Ton E; Kumánovics G; Coleiro B; Feierl E; Szucs G; Von Mühlen CA; Riccieri V; Novak S; Chizzolini C; Kotulska A; Denton C; Coelho PC; Kötter I; Simsek I; de la Pena Lefebvre PG; Hachulla E; Seibold JR; Rednic S; Stork J; Morovic-Vergles J; Walker UA Ann Rheum Dis; 2010 Oct; 69(10):1809-15. PubMed ID: 20551155 [TBL] [Abstract][Full Text] [Related]
11. Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis. Ostojic P; Stojanovski N Rheumatol Int; 2017 Mar; 37(3):363-368. PubMed ID: 28008457 [TBL] [Abstract][Full Text] [Related]
12. Risk factors and outcome of Thai patients with scleroderma renal crisis: a disease duration-matched case control study. Wangkaew S; Lertthanaphok S; Puntana S; Noppakun K Int J Rheum Dis; 2017 Oct; 20(10):1562-1571. PubMed ID: 28752678 [TBL] [Abstract][Full Text] [Related]
13. Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Fasano S; Riccardi A; Messiniti V; Caramaschi P; Rosato E; Maurer B; Smith V; Siegert E; De Langhe E; Riccieri V; Airó P; Mihai C; Avouac J; Zanatta E; Walker UA; Iannone F; García De la Peña Lefebvre P; Distler JHW; Vacca A; Distler O; Kowal-Bielecka O; Allanore Y; Valentini G Ann Rheum Dis; 2019 Dec; 78(12):1681-1685. PubMed ID: 31422354 [TBL] [Abstract][Full Text] [Related]
14. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Teixeira L; Mouthon L; Mahr A; Berezné A; Agard C; Mehrenberger M; Noël LH; Trolliet P; Frances C; Cabane J; Guillevin L; Ann Rheum Dis; 2008 Jan; 67(1):110-6. PubMed ID: 17557890 [TBL] [Abstract][Full Text] [Related]
18. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Campo A; Mathai SC; Le Pavec J; Zaiman AL; Hummers LK; Boyce D; Housten T; Champion HC; Lechtzin N; Wigley FM; Girgis RE; Hassoun PM Am J Respir Crit Care Med; 2010 Jul; 182(2):252-60. PubMed ID: 20339143 [TBL] [Abstract][Full Text] [Related]
19. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Becker M; Graf N; Sauter R; Allanore Y; Curram J; Denton CP; Khanna D; Matucci-Cerinic M; de Oliveira Pena J; Pope JE; Distler O; ; Ann Rheum Dis; 2019 Sep; 78(9):1242-1248. PubMed ID: 31227488 [TBL] [Abstract][Full Text] [Related]